About Us
STRATEGY
Corporate
Centaur Pharmaceuticals is a fully integrated Indian pharmaceutical player with proficiencies across API, Formulations, Clinical Research and Contract Manufacturing. Centaur has strategic alliances with global majors and innovators and is devoted to quality. The Centaur foot-print encompasses 120 countries.
API
India’s leading manufacturer and exporter of Psychotropic API. Centaur has API capabilities from conceptualisation to commercialization. Centaur’s portfolio includes 57 API, of which 38 have been pioneered for the first time in India. The API facility in Ambernath near Mumbai caters to US, Europe and other regulated markets. Our clientele includes Big pharma and Generic majors.
Formulations
Centaur is India’s 34th largest pharmaceutical firm by prescriptions with a strong presence in Asia, South America and Africa. Centaur has a pan India reach, with leadership across 6 therapy segments. Centaur manufactures Sinarest, India’s No.1 anti-cold, since 1996, exclusively at its state of the art USFDA approved Goa facility. Sinarest is the only brand in India to have won the ‘Brand of the Year for Marketing Excellence’, seven times in a row. Centaur has two WHO-GMP approved formulations facilities in Goa for India and ROW markets.
Oral Solid Dosage Manufacturing Facility I Pune
Centaur’s fully scalable 25,000 sqm finished dosage formulations facility, caters to international markets. The annual capacity of the facility is 3 billion tablets and 600 million capsules. The facility houses the formulations R&D and analytical development sections.
Oral Solid Dosage Manufacturing Facility II Goa
The state of the art, oral solid dosage manufacturing facility caters to US, Europe and ROW markets. The facility is spread over 4.5 lakh sqft, with a capacity of 5 billion tablets and 650 million capsules in blisters and bottles.
Clinical Research
LifeSan, the clinical research arm of Centaur conducts clinical trials, and BA-BE studies. The facility has been successfully inspected by USFDA and approved by CDSCO India.
Innovation
Centaur introduced Woxheal, a new chemical entity (NCE), with German collaboration, for the first time in the world, in India. Centaur conducted phase II and III clinical trials in India for Woxheal and then developed the API and formulations in house. Woxheal treats diabetic foot ulcer, which is an unmet need, and helps save precious limbs from amputation.
Centaur has entered into a strategic alliance with an American Biotech company to market Renadyl, a pre-probiotic to treat chronic kidney disease.
Centaur Pharmaceuticals continues to relentlessly pursue research-driven innovation, devotion to quality, and a deep-rooted commitment to building a healthier tomorrow. Together, we are transforming lives and shaping the future of healthcare. Onward and upward!